{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:58:23Z","timestamp":1789844303016,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11910-024-01363-w","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T07:02:02Z","timestamp":1721199722000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CGRP Modulating Therapies: An Update"],"prefix":"10.1007","volume":"24","author":[{"given":"Kate","family":"Bedrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulsi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"5","key":"1363_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019;59(5):659\u201381.","journal-title":"Headache"},{"key":"1363_CR2","doi-asserted-by":"crossref","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol [Internet]. 2018 Jun 1 [cited 2022 Jun 3];14(6):338\u201350. https:\/\/pubmed.ncbi.nlm.nih.gov\/29691490\/.","DOI":"10.1038\/s41582-018-0003-1"},{"key":"1363_CR3","doi-asserted-by":"publisher","unstructured":"Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. https:\/\/doi.org\/101080\/1472822220201724285 [Internet]. 2020 Feb 1 [cited 2022 Jun 3];24(2):91\u2013100. https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/14728222.2020.1724285.","DOI":"10.1080\/14728222.2020.1724285"},{"key":"1363_CR4","doi-asserted-by":"crossref","unstructured":"Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med [Internet]. 2011 [cited 2022 Jun 3];13:e36.","DOI":"10.1017\/S1462399411002067"},{"key":"1363_CR5","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol [Internet]. 1988 Feb 1 [cited 2022 Jun 3];23(2):193\u20136. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1002\/ana.410230214.","DOI":"10.1002\/ana.410230214"},{"key":"1363_CR6","doi-asserted-by":"crossref","unstructured":"PJ G. L E, R E. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol [Internet]. 1990 [cited 2021 Jul 15];28(2):183\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/1699472\/.","DOI":"10.1002\/ana.410280213"},{"key":"1363_CR7","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen. & J. CGRP may play a causative role in migraine."},{"key":"1363_CR8","doi-asserted-by":"crossref","unstructured":"Cernuda-Moroll\u00f3n E, Mart\u00ednez-Camblor P, Ram\u00f3n C, Larrosa D, Serrano-Pertierra E, Pascual J. Research Submissions CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin Type A in Chronic Migraine. 2014.","DOI":"10.1186\/1129-2377-15-S1-E24"},{"key":"1363_CR9","doi-asserted-by":"crossref","unstructured":"Cernuda-Moroll\u00f3n E, Ram\u00f3n C, Mart\u00ednez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain [Internet]. 2015 May 1 [cited 2022 Apr 20];156(5):820\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/25735000\/.","DOI":"10.1097\/j.pain.0000000000000119"},{"key":"1363_CR10","doi-asserted-by":"crossref","unstructured":"Garces F, Mohr C, Zhang L, Huang CS, Chen Q, King C et al. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab). Cell Rep [Internet]. 2020 Feb 11 [cited 2022 Jun 8];30(6):1714\u20131723.e6. https:\/\/pubmed.ncbi.nlm.nih.gov\/32049005\/.","DOI":"10.1016\/j.celrep.2020.01.029"},{"key":"1363_CR11","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S et al. Erenumab versus topiramate for the prevention of migraine-a randomised, double-blind, active-controlled phase 4 trial. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03828539."},{"key":"1363_CR12","doi-asserted-by":"crossref","unstructured":"The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache [Internet]. 2019 Jan 1 [cited 2022 Jun 8];59(1):1\u201318. https:\/\/pubmed.ncbi.nlm.nih.gov\/30536394\/.","DOI":"10.1111\/head.13456"},{"key":"1363_CR13","doi-asserted-by":"crossref","unstructured":"Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase\u00ae. Cephalalgia. 2023;43(4):3331024231158083.","DOI":"10.1177\/03331024231158083"},{"key":"1363_CR14","unstructured":"Vig SJ, Garza J, Tao Y. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. Headache [Internet]. 2022 [cited 2022 Jun 8]; https:\/\/pubmed.ncbi.nlm.nih.gov\/35467013\/."},{"key":"1363_CR15","doi-asserted-by":"crossref","unstructured":"Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M et al. Migraine and cardiovascular disease. Neurology [Internet]. 2010 Feb 23 [cited 2022 Jun 8];74(8):628\u201335. https:\/\/n.neurology.org\/content\/74\/8\/628.","DOI":"10.1212\/WNL.0b013e3181d0cc8b"},{"key":"1363_CR16","doi-asserted-by":"publisher","unstructured":"Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, De Boer I et al. CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP? J Headache Pain [Internet]. 2019 Mar 12 [cited 2022 Jun 8];20(1):1\u20137. https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s10194-019-0979-y.","DOI":"10.1186\/s10194-019-0979-y"},{"key":"1363_CR17","doi-asserted-by":"publisher","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C, Hypertension. A new safety risk for patients treated with erenumab. Headache J Head Face Pain [Internet]. 2021 Jan 1 [cited 2022 Jun 8];61(1):202\u20138. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/head.14051.","DOI":"10.1111\/head.14051"},{"key":"1363_CR18","doi-asserted-by":"crossref","unstructured":"Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B et al. Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache [Internet]. 2021 Oct 1 [cited 2022 Jun 8];61(9):1411\u201320. https:\/\/pubmed.ncbi.nlm.nih.gov\/34591982\/.","DOI":"10.1111\/head.14208"},{"key":"1363_CR19","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med [Internet]. 2019 Jul 11 [cited 2022 Jun 8];381(2):132\u201341. https:\/\/pubmed.ncbi.nlm.nih.gov\/31291515\/.","DOI":"10.1056\/NEJMoa1813440"},{"key":"1363_CR20","doi-asserted-by":"crossref","unstructured":"Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. Cephalalgia [Internet]. 2020 Aug 1 [cited 2022 Jun 8];40(9):935\u201348. https:\/\/pubmed.ncbi.nlm.nih.gov\/32050782\/.","DOI":"10.1177\/0333102420905321"},{"key":"1363_CR21","doi-asserted-by":"crossref","unstructured":"Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ et al. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache [Internet]. 2021 Oct 1 [cited 2022 Jun 8];61(9):1421\u201331. https:\/\/pubmed.ncbi.nlm.nih.gov\/34551130\/.","DOI":"10.1111\/head.14206"},{"key":"1363_CR22","doi-asserted-by":"crossref","unstructured":"Winner PK, Mcallister P, Chakhava G, Ailani J, Ettrup A, Mette ; et al. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack A Randomized Clinical Trial. 2021; https:\/\/jamanetwork.com\/.","DOI":"10.1001\/jama.2021.7665"},{"key":"1363_CR23","doi-asserted-by":"crossref","unstructured":"Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L et al. Does wearing off of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache [Internet]. 2022 Feb 1 [cited 2022 Jun 8];62(2):198\u2013207. https:\/\/pubmed.ncbi.nlm.nih.gov\/35076090\/.","DOI":"10.1111\/head.14257"},{"key":"1363_CR24","doi-asserted-by":"publisher","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine. Headache J Head Face Pain [Internet]. 2020 Oct 1 [cited 2022 Jul 10];60(9):2014\u201325. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/head.13951.","DOI":"10.1111\/head.13951"},{"key":"1363_CR25","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M, Paiva G, Lima S, Hours-Zesiger P et al. Long-term Efficacy and Safety of Erenumab. Neurology [Internet]. 2021 Jun 1 [cited 2022 Jul 12];96(22):e2724\u201335. https:\/\/n.neurology.org\/content\/96\/22\/e2724.","DOI":"10.1212\/WNL.0000000000012029"},{"key":"1363_CR26","doi-asserted-by":"publisher","unstructured":"Blumenfeld AM, Stevanovic DM, Ortega M, Cohen JM, Seminerio MJ, Yang R et al. No Wearing-Off Effect Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study. Headache J Head Face Pain [Internet]. 2020 Nov 1 [cited 2022 Jul 10];60(10):2431\u201343. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/head.13994.","DOI":"10.1111\/head.13994"},{"key":"1363_CR27","doi-asserted-by":"crossref","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia [Internet]. 2022 Apr 1 [cited 2022 Jun 8];42(4\u20135):291.","DOI":"10.1177\/03331024211048765"},{"key":"1363_CR28","doi-asserted-by":"publisher","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM et al. Ubrogepant for the Treatment of Migraine. N Engl J Med [Internet]. 2019 Dec 5 [cited 2021 Nov 8];381(23):2230\u201341. https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1813049.","DOI":"10.1056\/NEJMoa1813049"},{"key":"1363_CR29","doi-asserted-by":"crossref","unstructured":"RB JA. L, S H, K K, K L, M B, Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache [Internet]. 2020 Jan 1 [cited 2021 Jul 15];60(1):141\u201352. https:\/\/pubmed.ncbi.nlm.nih.gov\/31913519\/.","DOI":"10.1111\/head.13682"},{"issue":"7","key":"1363_CR30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/head.13862","volume":"60","author":"A Jakate","year":"2020","unstructured":"Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered with Sumatriptan and of the safety of Ubrogepant with triptans. Headache. 2020;60(7):1340\u201350.","journal-title":"Headache"},{"key":"1363_CR31","doi-asserted-by":"crossref","unstructured":"PJ RC, DA G, CM S, EG CMF. S, Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet (London, England) [Internet]. 2019 Aug 31 [cited 2021 Jul 15];394(10200):737\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/31311674\/.","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"1363_CR32","doi-asserted-by":"crossref","unstructured":"Jensen C, Lipton R, Blumenfeld A, Croop R, Thiry A, L\u2019Italien G et al. Rimegepant for the Acute treatment of Migraine in patients with a history of Triptan Treatment failure: pooled results from 3 phase 3 clinical trials (4914). Neurology. 2021;96(15 Supplement).","DOI":"10.1212\/WNL.96.15_supplement.4914"},{"key":"1363_CR33","unstructured":"L\u2019italien G, Popoff E, Johnston K, Mcgrath D, Conway CM, Powell L et al. Rimegepant 75\u00a0mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. https:\/\/us.sagepub.com\/en-us\/nam\/open-access-at-sage."},{"key":"1363_CR34","doi-asserted-by":"publisher","unstructured":"Johnston K, Harris L, Powell L, Popoff E, Coric V, L\u2019Italien G et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant \u2013 post hoc results from an open label safety study (BHV3000\u2013201). J Headache Pain [Internet]. 2022 Dec 1 [cited 2022 May 5];23(1):1\u20138. https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s10194-021-01378-5.","DOI":"10.1186\/s10194-021-01378-5"},{"key":"1363_CR35","doi-asserted-by":"crossref","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2021 Jan 2 [cited 2021 Nov 8];397(10268):51\u201360. http:\/\/www.thelancet.com\/article\/S0140673620325447\/fulltext.","DOI":"10.1016\/S0140-6736(20)32544-7"},{"issue":"6","key":"1363_CR36","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/head.14128","volume":"61","author":"E Popoff","year":"2021","unstructured":"Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, et al. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine. Headache. 2021;61(6):906\u201315.","journal-title":"Headache"},{"key":"1363_CR37","doi-asserted-by":"publisher","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al. Atogepant for the Preventive Treatment of Migraine. https:\/\/doi.org\/101056\/NEJMoa2035908 [Internet]. 2021 Aug 18 [cited 2021 Oct 11];385(8):695\u2013706. https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2035908.","DOI":"10.1056\/NEJMoa2035908"},{"key":"1363_CR38","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2021 Nov 15]; Available from: http:\/\/www.fda.gov\/medwatch."},{"key":"1363_CR39","unstructured":"Strassman AM, Melo-Carrillo A, Houle TT, Adams A, Brin MF, Burstein R. Atogepant \u2013 an orally-administered CGRP antagonist \u2013 attenuates activation of meningeal nociceptors by CSD: https:\/\/doi.org\/101177\/03331024221083544 [Internet]. 2022 Mar 25 [cited 2022 May 6];033310242210835."},{"key":"1363_CR40","doi-asserted-by":"crossref","unstructured":"Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. Headache [Internet]. 2021 Apr 1 [cited 2022 Jun 3];61(4):642\u201352. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33818780\/.","DOI":"10.1111\/head.14095"},{"key":"1363_CR41","doi-asserted-by":"crossref","unstructured":"Croop R, Madonia J, Conway C, Thiry A, Forshaw M, Murphy A, et al. Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2\/3 Dose-Ranging Clinical trial (4976). Neurology. 2021;96(15 Supplement).","DOI":"10.1212\/WNL.96.15_supplement.4976"},{"key":"1363_CR42","doi-asserted-by":"crossref","unstructured":"Bertz R, Donohue M, Madonia J, Bhardwaj R, Stringfellow J, Anderson M, et al. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004). Neurology. 2022;98(18 Supplement).","DOI":"10.1212\/WNL.98.18_supplement.1003"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-024-01363-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-024-01363-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-024-01363-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:30:09Z","timestamp":1724751009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-024-01363-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s11910-024-01363-w","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"6 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica Ailani, MD, reports personal fees from AbbVie, Aeon, Amgen, Axsome Dr. Reddy, Eli Lilly, eneura, Pfizer, GlaxoSmithKline, Gore, Impel, Parema, Linpharma, Lundbeck Merz, Neurolief, Scilex, Satsuma, Theranica, clinical trial support from AbbVie, Impel, Lundbeck, Parema . She has provided editorial services to Current Pain and Headache Reports, Medscape, and SELF magazine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}